{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Cassava Sciences, Inc. technically bullish or bearish?
As of May 1, 2025, Cassava Sciences, Inc. shows a mildly bearish trend due to daily moving averages and weekly Bollinger Bands indicating bearishness, despite some mixed signals from the MACD and KST.
Who are in the management team of Cassava Sciences, Inc.?
As of March 2022, the management team of Cassava Sciences, Inc. includes Mr. Remi Barbier as Chairman, President, and CEO, and Dr. Nadav Friedmann as Chief Medical and Operating Officer. The Board of Directors also features independent members such as Dr. Robert Gussin and Mr. Michael O'Donnell.
What does Cassava Sciences, Inc. do?
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s. It has a market cap of $100 million and reported a net profit loss of $23 million as of March 2025.
How big is Cassava Sciences, Inc.?
As of Jun 18, Cassava Sciences, Inc. has a market capitalization of 100.00 million, with recent quarterly net sales of 0.00 million and a net profit of -72.78 million. As of December 2024, the company reported shareholder's funds of 145.70 million and total assets of 157.53 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
